346 Fetal Cardiac Rhabdomyoma: a Case Report
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pleomorphic Adenoma of Buccal Mucosa: a Rare Case Report
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 16, Issue 3 Ver. XI (March. 2017), PP 75-78 www.iosrjournals.org Pleomorphic Adenoma of Buccal Mucosa: A Rare Case Report Ashwini Jangamashetti, BDS1, Siddesh Shenoy, MDS2, R.Krishna Kumar MDS3, Amol Jeur, MS4 1Post Graduate Student, Department Of Oral Medicine And Radiology, MARDC,Pune 2Reader, Department of oral Medicine and radiology, M.A Rangoonwala Dental College and Research Center, Pune (MARDC), 3Professor and HOD, Department of oral Medicine and Radiology, MARDC, Pune 4Assistant Professor in Department of General surgery, Krishna Medical College of KIMS Deemed University , Abstract: Pleomorphic adenoma is a benign tumor of the salivary gland that consists of a combination of epithelial and mesenchymal elements1. About 90% of these tumors occur in the parotid gland and 10% in the minor salivary glands2. Among intra oral pleomorphic adenomas buccal vestibule is among the rarest sites3. A case of pleomorphic adenoma of minor salivary glands in the buccal vestibule in a 36 year-old female is discussed4. It includes review of literature, clinical features, histopathology, radiological findings and treatment of the tumor, with emphasis on diagnosis4. The mass was removed by wide local excision with adequate margins5. Keywords: minor salivary gland, pleomorphic adenoma, tumor, parotid gland, vestibule, mesenchymal elements. I. Introduction Pleomorphic adenoma (PA) is defined by World Health Organization in 1972 as a circumscribed tumor characterized by its pleomorphic or mixed appearance clearly recognizable epithelial tissue being intermingled with tissue of mucoid, myxoid and chondroid appearance2. Among all salivary gland tumors, pleomorphic adenoma is the most frequently encountered lesion accounting for approximately 60% of all salivary gland neoplasms3. -
Soft Tissue Cytopathology: a Practical Approach Liron Pantanowitz, MD
4/1/2020 Soft Tissue Cytopathology: A Practical Approach Liron Pantanowitz, MD Department of Pathology University of Pittsburgh Medical Center [email protected] What does the clinician want to know? • Is the lesion of mesenchymal origin or not? • Is it begin or malignant? • If it is malignant: – Is it a small round cell tumor & if so what type? – Is this soft tissue neoplasm of low or high‐grade? Practical diagnostic categories used in soft tissue cytopathology 1 4/1/2020 Practical approach to interpret FNA of soft tissue lesions involves: 1. Predominant cell type present 2. Background pattern recognition Cell Type Stroma • Lipomatous • Myxoid • Spindle cells • Other • Giant cells • Round cells • Epithelioid • Pleomorphic Lipomatous Spindle cell Small round cell Fibrolipoma Leiomyosarcoma Ewing sarcoma Myxoid Epithelioid Pleomorphic Myxoid sarcoma Clear cell sarcoma Pleomorphic sarcoma 2 4/1/2020 CASE #1 • 45yr Man • Thigh mass (fatty) • CNB with TP (DQ stain) DQ Mag 20x ALT –Floret cells 3 4/1/2020 Adipocytic Lesions • Lipoma ‐ most common soft tissue neoplasm • Liposarcoma ‐ most common adult soft tissue sarcoma • Benign features: – Large, univacuolated adipocytes of uniform size – Small, bland nuclei without atypia • Malignant features: – Lipoblasts, pleomorphic giant cells or round cells – Vascular myxoid stroma • Pitfalls: Lipophages & pseudo‐lipoblasts • Fat easily destroyed (oil globules) & lost with preparation Lipoma & Variants . Angiolipoma (prominent vessels) . Myolipoma (smooth muscle) . Angiomyolipoma (vessels + smooth muscle) . Myelolipoma (hematopoietic elements) . Chondroid lipoma (chondromyxoid matrix) . Spindle cell lipoma (CD34+ spindle cells) . Pleomorphic lipoma . Intramuscular lipoma Lipoma 4 4/1/2020 Angiolipoma Myelolipoma Lipoblasts • Typically multivacuolated • Can be monovacuolated • Hyperchromatic nuclei • Irregular (scalloped) nuclei • Nucleoli not typically seen 5 4/1/2020 WD liposarcoma Layfield et al. -
Acral Manifestations of Soft Tissue Tumors Kristen M
Clinics in Dermatology (2017) 35,85–98 Acral manifestations of soft tissue tumors Kristen M. Paral, MD, Vesna Petronic-Rosic, MD, MSc⁎ Section of Dermatology, University of Chicago Pritzker School of Medicine, Chicago, IL Abstract This group of biologically diverse entities is united by topographic localization to the hands and feet. Categorizing tumors by body site narrows the differential into a short list of possibilities that can facil- itate accurate and rapid diagnosis. The goal of this review is to provide a practical approach to soft tissue tumors of acral locations for clinicians, pathologists, and researchers alike. What ensues in the following text is that tight coupling of the clinical picture and histopathologic findings should produce the correct diagno- sis, or at least an abbreviated differential. The salient clinicopathologic, immunohistochemical, and molec- ular features are presented alongside current treatment recommendations for each entity. © 2017 Elsevier Inc. All rights reserved. Introduction actin (SMA) and are deemed “myofibroblasts.”1 The tumors under this heading express combinations of CD34, FXIIIa, fi The entities presented herein are categorized on the basis of and SMA. The synthesis of collagen by broblasts translates fi fi morphogenesis (where possible) and by biologic potential as to a brous consistency that clinically imparts a rm texture benign, intermediate, and malignant neoplasms. on palpation, and, macroscopically, a gray-white or white-tan cut surface. The entities discussed next have no metastatic po- tential; that is, simple excision is adequate. Fibrous and related tissues: Benign lesions Fibroma of tendon sheath fi fl The ontogenetic classi cation of benign lesions re ects appar- Also known as tenosynovial fibroma, compared with other fi fi fi ent broblastic or broblast-like morphogenesis. -
Mesenchymal) Tissues E
Bull. Org. mond. San 11974,) 50, 101-110 Bull. Wid Hith Org.j VIII. Tumours of the soft (mesenchymal) tissues E. WEISS 1 This is a classification oftumours offibrous tissue, fat, muscle, blood and lymph vessels, and mast cells, irrespective of the region of the body in which they arise. Tumours offibrous tissue are divided into fibroma, fibrosarcoma (including " canine haemangiopericytoma "), other sarcomas, equine sarcoid, and various tumour-like lesions. The histological appearance of the tamours is described and illustrated with photographs. For the purpose of this classification " soft tis- autonomic nervous system, the paraganglionic struc- sues" are defined as including all nonepithelial tures, and the mesothelial and synovial tissues. extraskeletal tissues of the body with the exception of This classification was developed together with the haematopoietic and lymphoid tissues, the glia, that of the skin (Part VII, page 79), and in describing the neuroectodermal tissues of the peripheral and some of the tumours reference is made to the skin. HISTOLOGICAL CLASSIFICATION AND NOMENCLATURE OF TUMOURS OF THE SOFT (MESENCHYMAL) TISSUES I. TUMOURS OF FIBROUS TISSUE C. RHABDOMYOMA A. FIBROMA D. RHABDOMYOSARCOMA 1. Fibroma durum IV. TUMOURS OF BLOOD AND 2. Fibroma molle LYMPH VESSELS 3. Myxoma (myxofibroma) A. CAVERNOUS HAEMANGIOMA B. FIBROSARCOMA B. MALIGNANT HAEMANGIOENDOTHELIOMA (ANGIO- 1. Fibrosarcoma SARCOMA) 2. " Canine haemangiopericytoma" C. GLOMUS TUMOUR C. OTHER SARCOMAS D. LYMPHANGIOMA D. EQUINE SARCOID E. LYMPHANGIOSARCOMA (MALIGNANT LYMPH- E. TUMOUR-LIKE LESIONS ANGIOMA) 1. Cutaneous fibrous polyp F. TUMOUR-LIKE LESIONS 2. Keloid and hyperplastic scar V. MESENCHYMAL TUMOURS OF 3. Calcinosis circumscripta PERIPHERAL NERVES II. TUMOURS OF FAT TISSUE VI. -
The Role of Cytogenetics and Molecular Diagnostics in the Diagnosis of Soft-Tissue Tumors Julia a Bridge
Modern Pathology (2014) 27, S80–S97 S80 & 2014 USCAP, Inc All rights reserved 0893-3952/14 $32.00 The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors Julia A Bridge Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA Soft-tissue sarcomas are rare, comprising o1% of all cancer diagnoses. Yet the diversity of histological subtypes is impressive with 4100 benign and malignant soft-tissue tumor entities defined. Not infrequently, these neoplasms exhibit overlapping clinicopathologic features posing significant challenges in rendering a definitive diagnosis and optimal therapy. Advances in cytogenetic and molecular science have led to the discovery of genetic events in soft- tissue tumors that have not only enriched our understanding of the underlying biology of these neoplasms but have also proven to be powerful diagnostic adjuncts and/or indicators of molecular targeted therapy. In particular, many soft-tissue tumors are characterized by recurrent chromosomal rearrangements that produce specific gene fusions. For pathologists, identification of these fusions as well as other characteristic mutational alterations aids in precise subclassification. This review will address known recurrent or tumor-specific genetic events in soft-tissue tumors and discuss the molecular approaches commonly used in clinical practice to identify them. Emphasis is placed on the role of molecular pathology in the management of soft-tissue tumors. Familiarity with these genetic events -
Pathology and Genetics of Tumours of Soft Tissue and Bone
bb5_1.qxd 13.9.2006 14:05 Page 3 World Health Organization Classification of Tumours WHO OMS International Agency for Research on Cancer (IARC) Pathology and Genetics of Tumours of Soft Tissue and Bone Edited by Christopher D.M. Fletcher K. Krishnan Unni Fredrik Mertens IARCPress Lyon, 2002 bb5_1.qxd 13.9.2006 14:05 Page 4 World Health Organization Classification of Tumours Series Editors Paul Kleihues, M.D. Leslie H. Sobin, M.D. Pathology and Genetics of Tumours of Soft Tissue and Bone Editors Christopher D.M. Fletcher, M.D. K. Krishnan Unni, M.D. Fredrik Mertens, M.D. Coordinating Editor Wojciech Biernat, M.D. Layout Lauren A. Hunter Illustrations Lauren A. Hunter Georges Mollon Printed by LIPS 69009 Lyon, France Publisher IARCPress International Agency for Research on Cancer (IARC) 69008 Lyon, France bb5_1.qxd 13.9.2006 14:05 Page 5 This volume was produced in collaboration with the International Academy of Pathology (IAP) The WHO Classification of Tumours of Soft Tissue and Bone presented in this book reflects the views of a Working Group that convened for an Editorial and Consensus Conference in Lyon, France, April 24-28, 2002. Members of the Working Group are indicated in the List of Contributors on page 369. bb5_1.qxd 22.9.2006 9:03 Page 6 Published by IARC Press, International Agency for Research on Cancer, 150 cours Albert Thomas, F-69008 Lyon, France © International Agency for Research on Cancer, 2002, reprinted 2006 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. -
Mast Cell Infiltration and Leukotriene
Journal of Cancer Therapy, 2015, 6, 606-612 Published Online July 2015 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2015.67066 Mast Cell Infiltration and Leukotriene Receptor Expression in Various Tumors: Possible Clinical Application of Common Pathological Findings Concerned with Tumor Development Masao Sugamata*, Tomomi Ihara, Miho Sugamata Department of Pathology, Tochigi Institute of Clinical Pathology, Tochigi, Japan Email: *[email protected] Received 18 June 2015; accepted 18 July 2015; published 21 July 2015 Copyright © 2015 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract Since the mechanisms of the developmental processes of tumors remain unclear, early detection and early treatment of the tumors is necessary to save patients with malignant tumors. Therapies currently available to patients are surgery, chemotherapy, and radiotherapy. However, there are many patients who cannot be saved by such therapies. In this study, we found the common fea- tures of various tumor tissues, and we demonstrated the effect of therapeutics that target them by using experimental rats with spontaneous tumors. 26 kinds of human tumors (epithelial or me- senchymal origin, and malignant or benign) and Sprague-Dawley rats with spontaneous mammary gland tumors were examined by light and electron microscope. To detect of mast cells and leuko- triene receptor, toluidine blue stain and immunohistochemical stain were performed. The rats were orally administered one of leukotriene receptor antagonists. We found that the presence of numerous mast cells and expression of leukotriene receptors in various tumor (human tumors and rat spontaneous tumors). -
Cutaneous Fetal Rhabdomyoma a Case Report and Historical Review of the Literature
CASE REPORT Cutaneous Fetal Rhabdomyoma A Case Report and Historical Review of the Literature Sarah N. Walsh, MD* and Mark A. Hurt, MDw mas; such articles have documented different histologic Abstract: Fetal rhabdomyomas are well-documented tumors, types, local regrowth and possible malignancy, a broader affecting both children and adults that are composed of age distribution, various immunohistochemical staining immature striated muscle at the sixth to tenth-week stage of patterns, occurrence in particular syndromes, and their development. Although there is often a predilection for the head presence in a wide assortment of organs and anatomic and neck region, these tumors have been identified in a wide sites.1,2,4–8,11,15,16,18,20–25,29,33 To the best of our knowl- array of anatomic sites. A primary cutaneous presentation, edge, however, fetal rhabdomyoma has never been however, has not yet been described. We report the first case of a diagnosed definitively in the skin. We present the first fetal rhabdomyoma arising in the skin of a 1-year old girl. After case of a cutaneous fetal rhabdomyoma found in a 1- the initial biopsy, an incomplete excision was performed with year-old girl with a lesion on the chin. tumor present histologically at multiple surgical margins. In a follow-up period of 54 months, there has been no lesional regrowth or evidence of further progression. This case is CASE REPORT detailed, in addition to a literature-based review of the historical The patient was a 1-year-old girl seen by a pediatric and conceptual development of the neoplasm known as fetal dermatologist for a chin lesion that had been present for the past 10 months but had not changed noticeably during that period. -
Integrated Data Analysis Reveals Uterine Leiomyoma Subtypes with Distinct Driver Pathways and Biomarkers
Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers Miika Mehinea,b, Eevi Kaasinena,b, Hanna-Riikka Heinonena,b, Netta Mäkinena,b, Kati Kämpjärvia,b, Nanna Sarvilinnab,c, Mervi Aavikkoa,b, Anna Vähärautiob, Annukka Pasanend, Ralf Bützowd, Oskari Heikinheimoc, Jari Sjöbergc, Esa Pitkänena,b, Pia Vahteristoa,b, and Lauri A. Aaltonena,b,e,1 aMedicum, Department of Medical and Clinical Genetics, University of Helsinki, Helsinki FIN-00014, Finland; bResearch Programs Unit, Genome-Scale Biology, University of Helsinki, Helsinki FIN-00014, Finland; cDepartment of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki FIN-00029, Finland; dDepartment of Pathology and HUSLAB, Helsinki University Hospital, University of Helsinki, Helsinki FIN-00014, Finland; and eDepartment of Biosciences and Nutrition, Karolinska Institutet, SE-171 77, Stockholm, Sweden Edited by Bert Vogelstein, Johns Hopkins University, Baltimore, MD, and approved December 18, 2015 (received for review September 25, 2015) Uterine leiomyomas are common benign smooth muscle tumors that with deletions affecting collagen, type IV, alpha 5 and collagen, type impose a major burden on women’s health. Recent sequencing studies IV, alpha 6 (COL4A5-COL4A6) may constitute a rare fourth subtype have revealed recurrent and mutually exclusive mutations in leiomyo- (4). HMGA2 and MED12 represent the two most common driver mas, suggesting the involvement of molecularly distinct pathways. In genes and together contribute to 80–90% of all leiomyomas (5). this study, we explored transcriptional differences among leiomyomas Less frequently, leiomyomas harbor 6p21 rearrangements af- harboring different genetic drivers, including high mobility group fecting high mobility group AT-hook 1 (HMGA1) (6). -
Lipomata of the Uterus
University of Louisville ThinkIR: The University of Louisville's Institutional Repository Electronic Theses and Dissertations 1940 Lipomata of the uterus. DeLou Perrin Hall University of Louisville Follow this and additional works at: https://ir.library.louisville.edu/etd Part of the Medicine and Health Sciences Commons Recommended Citation Hall, DeLou Perrin, "Lipomata of the uterus." (1940). Electronic Theses and Dissertations. Paper 2035. https://doi.org/10.18297/etd/2035 This Master's Thesis is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact [email protected]. UNIVERSrTY .OF LOUISVILLE LIPOMATA OF THE UTERUS " A Dis.sertation Submitted to the Faculty Of the Graduate School of the University of Louisville In Partial Fulfillment of the Requirements for the Degree Of Master of Science Department .of Pathology By DeLou Perrin Hall,.. Year 1940 '. PREFAOE In the writing of this thesis I have spent many happy hours in search of literature relative to Lipomata of the uterus, the task has been enjoyable because of the ever stimulating influence of the Frofessor of Pathology in the University of Louisville, Dr. A. James Miller, to whom I am grateful. To my associate and erstwhile Professor of Surgery, Dr. J. Garland Sherrill, whose profound wisdom has been a tlLamp unto my- feet and a light unto my- path," my sincere thanks. -
Dermoscopy As an Adjuvant Tool for Detecting Skin Leiomyomas In
Diluvio et al. BMC Dermatology 2014, 14:7 http://www.biomedcentral.com/1471-5945/14/7 CASE REPORT Open Access Dermoscopy as an adjuvant tool for detecting skin leiomyomas in patient with uterine fibroids and cerebral cavernomas Laura Diluvio1*, Claudia Torti1, Alessandro Terrinoni2, Eleonora Candi2, Raffaella Piancatelli3, Emilio Piccione3, Evelin Jasmine Paternò4, Sergio Chimenti1, Augusto Orlandi5, Elena Campione1† and Luca Bianchi1† Abstract Background: Hereditary syndromes frequently need the cooperation of different specialties to increase diagnostic competence. Multiple cutaneous and uterine leiomyomatosis syndrome is a rare autosomal dominant disorder caused by the mutations of the fumarate hydratase gene, demonstrated in 80 to 100 percent of affected individuals. This can be linked to an increased risk of renal cancer in both sexes. The skin involvement is described to highlight the diagnostic role of the cutaneous counterpart in identifying this rare syndrome. Case presentation: A 37-year-old woman suffering from several uterine fibroids presented multiple, painful, papulo-nodules on her left subscapular side, both forearms and legs. The patient underwent surgery on six lesions: five were leiomyomas, whilst one was a dermatofibroma. Genetic sequencing did not evidence known fumarate hydratase gene mutations. Dermoscopy showed a brown delicate pigmented network and included leiomyomas among the non-melanocytic benign skin tumours featuring a dermatofibroma-like pattern. Abdominal computerized-tomography scan did not reveal renal cancer, but brain magnetic resonance imaging showed one asymptomatic cerebral cavernoma. The patient benefited from the surgical removal of the five larger cutaneous lesions and from gabapentin, which relieved her pain. Conclusions: This observation highlights the usefulness of dermoscopy in the diagnosis of cutaneous leiomyomas disclosing multiple cutaneous and uterine leiomyomatosis syndrome. -
RHABDOMYOMA of the OVARY Tumors of Striated Muscle Are Sufficiently Rare to Make the Observation of a New and Characteristic
RHABDOMYOMA OF THE OVARY H. E. HIMWICH From the Department oj Pathology, Cornell University Medical College, New York Received for publication, December 12, 1919 Tumors of striated muscle are sufficiently rare to make the observation of a new and characteristic case worthy of record. The rhabdomyoma which is the subject of the present discussion is of special interest because of the peculiar forms assumed by the myogenic cells and the wide variations of structure in the tumor. At the present time a detailed discussion of the literature of this neoplasm is unnecessary; but the facts which are of more direct bearing on the present case may be mentioned. Bene- nati’s list of 65 cases was published in 1903; and the cases reported since then do not show any material change in the relative frequency of this tumor in the various pmts of the body. They may be divided according to the regions in which they occur. Rhabdomyoma is found most often in the genito- urinary tract. There are 39 cases occurring in this region: kid- ney, 13; testis, 9; uterus, 6; pelvis of the kidney, 3; vagina, 3; bladder, 3; ovary or uterus, 1; ovary, 2. The tumor of the ovary described by Virchow in 1850 was a papillary cystic rhabdo- myosarcoma, some of the papillae being formed of striated muscle. A second rhabdomyoma of the ovary was reported by Vignard. It was similar to the tumor about to be described, the greater part being striated muscular tissue with cystic degeneration at one extremity. Wolfensberger noted the frequency of this tumor in the neck and adjoining regions, which stand second to the genitourinary tract with 9 cases.